Abstract
Korber et al. present evidence that there are now more SARS-CoV-2 viruses circulating in the human population globally that have the G614 form of the Spike protein versus the D614 form that was originally identified from the first human cases in Wuhan, China. Follow-up studies show that patients infected with G614 shed more viral nucleic acid compared with those with D614, and G614-bearing viruses show significantly higher infectious titers in vitro than their D614 counterparts.
| Original language | English |
|---|---|
| Pages (from-to) | 812-827.e19 |
| Journal | Cell |
| Volume | 182 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 20 2020 |
Keywords
- COVID-19
- PCR cycle threshold
- SARS-CoV-2
- Spike
- antibody
- diversity
- evolution
- infectivity
- neutralization
- pseudovirus
Fingerprint
Dive into the research topics of 'Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Tracking Changes in SARS-CoV-2 Spike : Evidence that D614G Increases Infectivity of the COVID-19 Virus. / Sheffield COVID-19 Genomics Group, Members of Sheffield COVID-19 Genomics Group.
In: Cell, Vol. 182, No. 4, 20.08.2020, p. 812-827.e19.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Tracking Changes in SARS-CoV-2 Spike
T2 - Evidence that D614G Increases Infectivity of the COVID-19 Virus
AU - Sheffield COVID-19 Genomics Group, Members of Sheffield COVID-19 Genomics Group
AU - Korber, Bette
AU - Fischer, Will M.
AU - Gnanakaran, Sandrasegaram
AU - Yoon, Hyejin
AU - Theiler, James
AU - Abfalterer, Werner
AU - Hengartner, Nick
AU - Giorgi, Elena E.
AU - Bhattacharya, Tanmoy
AU - Foley, Brian
AU - Hastie, Kathryn M.
AU - Parker, Matthew D.
AU - Partridge, David G.
AU - Evans, Cariad M.
AU - Freeman, Timothy M.
AU - de Silva, Thushan I.
AU - Angyal, Adrienne
AU - Brown, Rebecca L.
AU - Carrilero, Laura
AU - Green, Luke R.
AU - Groves, Danielle C.
AU - Johnson, Katie J.
AU - Keeley, Alexander J.
AU - Lindsey, Benjamin B.
AU - Parsons, Paul J.
AU - Raza, Mohammad
AU - Rowland-Jones, Sarah
AU - Smith, Nikki
AU - Tucker, Rachel M.
AU - Wang, Dennis
AU - Wyles, Matthew D.
AU - McDanal, Charlene
AU - Perez, Lautaro G.
AU - Tang, Haili
AU - Moon-Walker, Alex
AU - Whelan, Sean P.
AU - LaBranche, Celia C.
AU - Saphire, Erica O.
AU - Montefiori, David C.
N1 - Funding Information: We thank Andrew McMichael, Sarah Rowland-Jones, and Xiao-Ning Xu for bringing together the clinical and theory teams. We thank Anthony West for pointing out the 5′ UTR G-clade mutation; George Ellison for suggestions regarding clinical data analyses; Barbara Imperiali for insights regarding the structural implications of the D614G change; and Rachael Mansbach, Srirupa Chakraborty, and Kien Nguyen for sharing preliminary MD data. We thank Davey Smith and Stephen Rawlings of UCSD and Alessandro Sette, Jennifer M. Dan, and Shane Crotty of LJI for survivor sera and Sharon Schendel for manuscript edits. We acknowledge Barney Graham, Kizzmekia Corbett, Nicole Doria-Rose, Adrian McDermott, and John Mascola at the Vaccine Research Center, NIH for reagents and assistance with the lentivirus-based SARS-CoV-2 infection assay and Elize Domin for technical support. The Sheffield COVID-19 Genomics Group is part of the COG-UK CONSORTIUM, supported by the Medical Research Council (MRC), part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR), and Genome Research Limited , operating as the Wellcome Sanger Institute . T.I.d.S. is supported by a Wellcome Trust intermediate clinical fellowship ( 110058/Z/15/Z ). M.P. was funded by the NIHR Sheffield Biomedical Research Centre (BRC). B.K., E.E.G., T.B., N.H., W.M.F., H.Y., and W.A. were supported by LANL LDRD projects 20200554ECR and 20200706ER and through NIH NIAID , DHHS Interagency Agreement AAI12007-001-00000 . D.S. acknowledges support from the John and Mary Tu Foundation and the San Diego CFAR AI036214. A.S. and S.C. acknowledge support from NIH NIAID AI42742 (Cooperative Centers for Human Immunology). E.O.S. acknowledges support from CoVIC INV-006133 of the COVID-19 Therapeutics Accelerator , supported by the Bill and Melinda Gates Foundation , Mastercard , Wellcome and private philanthropic support, the Overton family , and a FastGrant from Emergent Ventures in aid of COVID-19 research. We gratefully acknowledge the team at GISAID for creating SARS-CoV-2 global database and the many people who provided sequence data ( Table S1 ). Funding Information: We thank Andrew McMichael, Sarah Rowland-Jones, and Xiao-Ning Xu for bringing together the clinical and theory teams. We thank Anthony West for pointing out the 5? UTR G-clade mutation; George Ellison for suggestions regarding clinical data analyses; Barbara Imperiali for insights regarding the structural implications of the D614G change; and Rachael Mansbach, Srirupa Chakraborty, and Kien Nguyen for sharing preliminary MD data. We thank Davey Smith and Stephen Rawlings of UCSD and Alessandro Sette, Jennifer M. Dan, and Shane Crotty of LJI for survivor sera and Sharon Schendel for manuscript edits. We acknowledge Barney Graham, Kizzmekia Corbett, Nicole Doria-Rose, Adrian McDermott, and John Mascola at the Vaccine Research Center, NIH for reagents and assistance with the lentivirus-based SARS-CoV-2 infection assay and Elize Domin for technical support. The Sheffield COVID-19 Genomics Group is part of the COG-UK CONSORTIUM, supported by the Medical Research Council (MRC), part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR), and Genome Research Limited, operating as the Wellcome Sanger Institute. T.I.d.S. is supported by a Wellcome Trust intermediate clinical fellowship (110058/Z/15/Z). M.P. was funded by the NIHR Sheffield Biomedical Research Centre (BRC). B.K. E.E.G. T.B. N.H. W.M.F. H.Y. and W.A. were supported by LANL LDRD projects 20200554ECR and 20200706ER and through NIH NIAID, DHHS Interagency Agreement AAI12007-001-00000. D.S. acknowledges support from the John and Mary Tu Foundation and the San Diego CFAR AI036214. A.S. and S.C. acknowledge support from NIH NIAID AI42742 (Cooperative Centers for Human Immunology). E.O.S. acknowledges support from CoVIC INV-006133 of the COVID-19 Therapeutics Accelerator, supported by the Bill and Melinda Gates Foundation, Mastercard, Wellcome and private philanthropic support, the Overton family, and a FastGrant from Emergent Ventures in aid of COVID-19 research. We gratefully acknowledge the team at GISAID for creating SARS-CoV-2 global database and the many people who provided sequence data (Table S1). Conceptualization, B.K. and D.C.M.; Methodology, B.K. W.M.F. J.T. N.H. E.O.S. and D.C.M.; Software, W.M.F. J.T. H.Y. W.A. N.H. E.E.G. T.B. T.M.F. M.D.P. and B.K.; Validation, E.O.S. D.C.M. J.T. B.K. B.F. and N.H.; Formal Analysis, B.K. J.T. N.H. W.M.F. S.G. M.D.P. T.M.F. D.G.P. C.M.E. T.I.d.S. T.B. and E.E.G.; Investigation, E.O.S. D.C.M. K.M.H. C.M.E. D.G.P. L.G.P. H.T. A.M.-W. S.P.W. C.C.L. and T.I.d.S.; Writing ? Original Draft, B.K. W.M.F. S.G. D.C.M. and E.O.S; Writing ? Review & Editing, T.I.d.S. C.C.L. E.E.G. N.H. H.Y. and T.B.; Visualization, B.K. E.O.S. J.T. N.H. W.M.F. E.E.G. and S.G.; Supervision, B.K. D.C.M. E.O.S. T.I.d.S. and S.P.W.; Funding Acquisition, B.K. E.E.G. D.C.M. S.G. E.O.S. and T.I.d.S. The authors declare no competing interests. Publisher Copyright: © 2020
PY - 2020/8/20
Y1 - 2020/8/20
N2 - Korber et al. present evidence that there are now more SARS-CoV-2 viruses circulating in the human population globally that have the G614 form of the Spike protein versus the D614 form that was originally identified from the first human cases in Wuhan, China. Follow-up studies show that patients infected with G614 shed more viral nucleic acid compared with those with D614, and G614-bearing viruses show significantly higher infectious titers in vitro than their D614 counterparts.
AB - Korber et al. present evidence that there are now more SARS-CoV-2 viruses circulating in the human population globally that have the G614 form of the Spike protein versus the D614 form that was originally identified from the first human cases in Wuhan, China. Follow-up studies show that patients infected with G614 shed more viral nucleic acid compared with those with D614, and G614-bearing viruses show significantly higher infectious titers in vitro than their D614 counterparts.
KW - COVID-19
KW - PCR cycle threshold
KW - SARS-CoV-2
KW - Spike
KW - antibody
KW - diversity
KW - evolution
KW - infectivity
KW - neutralization
KW - pseudovirus
UR - http://www.scopus.com/inward/record.url?scp=85087676352&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2020.06.043
DO - 10.1016/j.cell.2020.06.043
M3 - Article
C2 - 32697968
AN - SCOPUS:85087676352
VL - 182
SP - 812-827.e19
JO - Cell
JF - Cell
SN - 0092-8674
IS - 4
ER -